Strong growth for vet products group Dechra
Strong growth across its existing portfolio has enabled veterinary products supplier Dechra Pharmaceuticals to deliver a positive set of full year results.
In the year to June 30, 2017, revenue rose 28.3% at constant exchange rates to £359.3m (2016: £247.6m), underlying pre-tax profit was up 38% to £77m (2016: £49.7m). Underlying earnings per share rose 35% to 64.33p (2016: 42.65p) and the board has recommended a final dividend of 21.44p (2016: 18.46p), a rise of 16%.
It said both the core business and new acquisitions were ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
